Scientific Industries (SCND) investor relations material

Executive summary

• Revenue for Q2 2026 increased 36% year-over-year to $1.47M, driven by higher Benchtop Laboratory Equipment and Bioprocessing Systems sales.

• Gross margin improved to 42.3% from 34.8% year-over-year, reflecting a favorable product mix and higher-margin DOTS product sales.

• Operating loss narrowed to $1.27M from $1.82M in Q2 2025, aided by cost reductions in G&A and selling expenses.

• Net loss from continuing operations was $1.23M for Q2 2026, with discontinued operations contributing $273K in income.

• The Genie Division sale in August 2025 continues to impact results, with ongoing transition and supply agreements.

Financial highlights

• Q2 2026 revenue: $1.47M (up from $1.08M in Q2 2025); six-month revenue: $2.70M (up from $2.02M year-over-year).

• Gross profit margin: 42.3% in Q2 2026 vs. 34.8% in Q2 2025; six-month margin: 40.5% vs. 35.6%.

• Operating expenses for Q2 2026: G&A $553.9K, Selling $647.1K, R&D $694.5K.

• Net loss for Q2 2026: $1.20M; six-month net loss: $2.87M.

• Cash and equivalents at June 30, 2026: $616.5K; investment securities: $3.93M.

Outlook and guidance

• Management expects continued negative cash flows from operations due to ongoing investment in Bioprocessing Systems.

• Cash from the Genie Division sale and related agreements is expected to support operations for at least one year.

• No formal revenue or earnings guidance provided.